New mTOR inhibitor for renal cell cancer.
Wilkes
Gail M
GM
Boston Medical Center, Boston, Massachusetts, USA.
D001682:Biological Availability; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000451:nursing; D004347:Drug Interactions; D000068338:Everolimus; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000451:nursing; D009859:Oncology Nursing; D010353:Patient Education as Topic; D011494:Protein Kinases / Q000187:drug effects*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases
D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus